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Hematopoietic stem cells (HSCs) are a rare population residing at the apex of the 
hematopoietic hierarchy [1]. HSCs have the capacity to self-renew and differentiate into all 
blood cell types, thus they play a key role in hematopoietic cell transplantation (HCT) [2]. 
HCT is widely used as a curative therapy for numerous malignant and non-malignant 
hematological and even non-hematological diseases [3]. The fast developing field of gene 
editing techniques, including ZFNs, TALENs and CRISPR-Cas9, broaden usage of HCT in 
clinical therapy of diseases caused by genetic mutations [4]. i.e. β-thalassaemia or Sickle 
Cell Disease (SCD) may possibly be interrogated by CRISPR based gene editing of β-globin 
in HSCs from patients [5]. However, efficient gene editing and infusion of the gene edited 
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HSC into patients requires sufficient numbers of donor HSC. In addition, when cord blood 
(CB) is used as the source of HSC for HCT, rare HSC numbers in single CB units may lead 
to delayed hematopoietic recovery in recipients [6]. It is thus important in some cases to 
develop efficient means that can overcome limited HSC numbers to enhance the efficacy of 
HCT.
Efforts are underway by many scientific groups to develop potential ways to improve 
engraftment of HSC. This includes mitigating EPHOSS [7], enhancing HSC homing 
efficiency [8–9], promoting ex vivo expansion [10–12], and by reprogramming iPS or 
endothelial cells to human HSC [13–14]. However, most of these methods have not yet been 
adapted for clinical use, and there is still an urgent need to dissect the mechanisms behind 
these encouraging processes. Rigorous phenotypic analysis of HSC is an easily accessible 
and important method to evaluate the function of a heterogeneous cell population from bone 
marrow or blood samples. The rigorous phenotyping identity of human HSC identity was 
confirmed at a single cell level [15]. In general, freshly isolated human HSC are defined as 
CD34+CD38−CD45RA−CD90+CD49f+. However, we still don’t know if all cells in different 
circumstances, especially under stress conditions such as ex-vivo expansion, that are 
identified by CD34+CD38−CD45RA−CD90+CD49f+ are functional HSC with long-term 
repopulating capacity.
In a compound screen for agonists of human CB HSC ex vivo expansion, we found that 100 
nM 12-deoxyphorbol-13-O-phenylacetate-20-acetate (DOPPA), a weak phorbol ester, 
significantly and greatly expands cytokine (stem cell factor (SCF), thrombopoietin (TPO), 
Flt-3 ligand (FL)) -stimulated phenotypic CB HSC population (CD34+CD38−CD45RA
−CD90+CD49f+) (Figure 1A). Compared with the vehicle control cultured group, the 
DOPPA group contains 12.4-fold more phenotypic-defined HSCs after 4-days ex vivo 
culture (Figure 1B). The phenotypic HSC number in DOPPA-treated group was ~2.5 fold 
greater than that seen the SR1 and UM171-treated groups at this 4-day culture time (Figure 
1B).
We then examined the effect of DOPPA treatment on hematopoietic progenitor cells (HPCs). 
DOPPA significantly increased numbers of CB colony-forming unit (CFU) granulocyte/
macrophage (GM), but not granulocyte, erythroid, macrophage, megakaryocyte (CFU-
GEMM) progenitors after 4 days ex vivo culture (Figure 1C), suggesting that DOPPA 
treatment selectively promotes ex vivo expansion of functionally recognizable granulocyte-
macrophage progenitors.
In order to determine if the DOPPA expanded phenotypic HSC population had repopulating 
or increased repopulating capacity in vivo, we performed limiting dilution analysis to 
quantify SCID-repopulating cells (SRCs) by intravenous (i.v.) injection in sublethally-
irradiated NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mice. The SRC frequency of DOPPA -
cultured CB CD34+ cells and human CD45+ cell chimerism did not significantly increase 
compared with that of uncultured CD34+ cells and vehicle control-treated CD34+ cells 
(Figure 1D–F; Supplementary Table 1), whereas numerous studies by others,10,11 and 
ourselves (unpublished data) have shown significantly enhanced SRCs after ex-vivo 
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expansion with SR1 and UM171. These data strongly suggest that the DOPPA-expanded 
phenotypically-defined HSC were not active as engrafting HSC.
Interestingly, we noticed that phenotypic HSC were significantly increased if we cultured 
the CD34+ cells just for 24 hours with a higher concentration of DOPPA (1μM) or other 
phorbol esters, including phorbol-12-myristate-13-acetate (PMA) (Supplementary Figure 
1A-B). We performed in vivo transplantation experiments to examine if PMA-induced 
phenotypic HSC have long-term engrafting capacity. 10,000 vehicle or PMA-cultured 
CD34+ cells were transplanted into sublethally-irradiated NSG mice. The human cell 
engraftment in the BM of the NSG recipients was determined 16 weeks after transplantation. 
Our data showed that CD34+ cells cultured with DOPPA or PMA did not engraft better than 
the cells cultured with vehicle control (Supplementary Figure 1C-D). To exclude the 
possibility that PMA might affect the homing efficiency of CD34+ cells, we did homing 
experiments to examine the human cell percentage engrafted into the bone marrow of the 
recipient NSG mice 24 hours after transplantation. We found that PMA treatment did not 
significantly change the homing efficiency of CB HSC and HPC (Supplementary Figure 2A-
B). Together, these data demonstrate that the PMA-induced phenotypic HSC after ex vivo 
culture with cytokines were not capable of functional engraftment with long-term 
repopulating activity.
To understand mechanisms behind the unusual inconsistency between ex vivo HSC 
phenotyping analysis and in vivo functional evaluation, we did RNA-sequencing analysis to 
check the transcriptome of vehicle and DOPPA-treated CD34+ cells after 4 days ex-vivo 
culture. We noticed that expression of many genes which encode cell surface proteins 
including ITGA6 (CD49f) were significantly up-regulated, FDR-adjusted p-value < 0.01 and 
the fold change (FC) > 2, by DOPPA treatment (Figure 2A). Gene ontology (GO) analysis 
revealed that many GO functions related to cell surface or plasma membrane related GOs 
which all include ITGA6 were significantly enriched in up-regulated differentially expressed 
genes (DEGs) including ITGA6 after DOPPA treatment (Figure 2B). Quantitative PCR 
analysis further demonstrated that ITGA6 mRNA levels apparently increased in DOPPA-
treated CD34+ HSCs and HPCs (Figure 2C). We also checked mRNA expression of 
THY1(CD90), another marker of human HSC, the signal of which was not detected by 
RNA-seq analysis due to its low abundance. The THY1 mRNA level was largely increased 
in DOPPA treated CD34+ HSCs and HPCs (Figure 2C). Flow cytometry analysis showed 
that ITGA6 and THY1 surface expression was largely promoted by DOPPA (Supplementary 
Figure 2C-D). Increased ITGA6 expression in DOPPA treated CD34+ cells was further 
confirmed by T-distributed Stochastic Neighbor Embedding (tSNE) analysis (Figure 2D). 
These data indicated that DOPPA treatment promoted transcription and cell surface 
expression of ITGA6 and THY1, and thus had changed the percentage of the 
phenotypically-defined cells during ex vivo culture. We also found many genes involved in 
myeloid differentiation that were significantly enriched by DOPPA (Supplementary Figure 
2E-F), consistent with the increased numbers of CFU-GM we had detected (Figure 1C). 
These data may partly explain the DOPPA treatment-induced expansion of CFU-GM.
Phenotypic analysis of HSCs is a widely used approach to relatively quickly sort or quantify 
numbers of HSC, allowing for a rapid read-out of these cells. However, not all published 
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studies have focused on the correlation between the phenotyping and reconstituting capacity 
of the cells. Phorbol ester short treatment significantly changed the transcription and 
expression of cell surface markers used to define HSC, including ITGA6 and THY1. Our 
findings provide an excellent example for investigators in this field that it is crucial for full 
analysis of effects on HSC function that engrafting studies always be performed to confirm 
functional activities, as phenotype may not always recapitulate function. The quantification 
of HSC is based on expression of several cell surface markers. In some circumstances, 
mRNA expression needs to be considered to exclude the possibility that the transcription of 
those genes encoding HSC markers were changed by the treatment. Future study will likely 
need to be performed to identify candidate HSC markers that can reflect the reconstituting 
capacity of the cells in different circumstances, especially under stress conditions.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. DOPPA expands human cord blood phenotypic hematopoietic stem cells without 
repopulating capacity.
(A) Representative FACS plots (from n = 3 independent experiments) showing ex vivo 
expansion of cord blood (CB) phenotypic hematopoietic stem cells (pHSCs) after treatment 
with vehicle (DMSO), DOPPA (100 nM), SR1 (1μM), UM171 (100 nM) for 4 days. The 
pHSC population was defined as CD34+CD38−CD45RA−CD49f+CD90+ cells.
(B) Quantification of pHSCs expanded by vehicle (DMSO), DOPPA (100 nM), SR1 (1 μM), 
or UM171 (100 nM) at day 4. Data are shown as mean±s.e.m.
(C) Quantification of CFU numbers in 50,000 CD34+ cells (for each well of the culture 
plate) of day 0 uncultured cells and the progeny of an equivalent number of CD34+ cells 
expanded by vehicle or DOPPA for 4 day (n = 9 cultures from three independent 
experiments per group). Data are shown as mean±s.e.m.
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(D) Poisson distribution analysis plot of the frequency of human SRCs in uncultured CB 
CD34+ cells (black line; group A) or in the progeny of an equivalent number of CD34+ cells 
that were cultured with vehicle (red line; group B) or DOPPA (green line; group C) for 4 d. 
(n = 7 to 10 mice per group). Circles represent the percentage of negative mice for each 
dose. Solid lines indicate the best-fit linear model for each data set. Dashed lines represent 
95% confidence intervals.
(E) SRCs (line in the box) in 1 × 106 CD34+ cells for each group and the relative 95% 
confidence intervals (box) are shown. L-Calc™ Software was used for Poisson statistical 
analysis. n.s. marks non-significant difference.
(F) Human CD45+ cell chimerism in the bone marrow of NSG recipient mice 4 months after 
transplantation. Data are shown as mean±s.e.m. One-way ANOVA followed by Tukey test 
was performed in figures (B), (C) and (F). *p<0.05; ***p<0.001.
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Figure 2. DOPPA treatment promotes transcription of genes encoding cell surface proteins 
including ITGA6 and THY1.
(A) Heat map showing differentially expressed genes (DEGs) associated with “cell surface” 
up-regulated by DOPPA treatment. Each group has three replicates (r1, r2, r3).
(B) Selected GOs that are significantly enriched in DOPPA-treated group compared with 
vehicle control group.
(C) Quantitative real-time PCR analysis of ITGA6 and THY1 expression in vehicle or 
DOPPA treated CD34+ cell. Data are shown as mean±s.d. Student’s t-test was performed. 
**p<0.01.
(D) tSNE analysis showing ITGA6 expression in vehicle or DOPPA treated CD34+ cells. 
CD34-APC gate was selected as the input. tSNE analysis was performed using FlowJo_V10 
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software to compare ITGA6 expression in vehicle or DOPPA treated groups. The circles 
indicate CD34+ cells with high levels of ITGA6.
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